KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $67951.0.

  • Inovio Pharmaceuticals' Capital Expenditures changed N/A to $67951.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $158254.0, marking a year-over-year decrease of 6755.97%. This contributed to the annual value of $487832.0 for FY2024, which is 5202.09% up from last year.
  • Inovio Pharmaceuticals' Capital Expenditures amounted to $67951.0 in Q3 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Capital Expenditures peaked at $643658.0 during Q4 2021, and registered a low of $23915.0 during Q2 2023.
  • In the last 5 years, Inovio Pharmaceuticals' Capital Expenditures had a median value of $168614.0 in 2021 and averaged $211142.9.
  • In the last 5 years, Inovio Pharmaceuticals' Capital Expenditures surged by 48431.23% in 2021 and then tumbled by 9381.13% in 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' Capital Expenditures (Quarter) stood at $643658.0 in 2021, then tumbled by 74.35% to $165109.0 in 2022, then tumbled by 85.52% to $23915.0 in 2023, then skyrocketed by 87.56% to $44856.0 in 2024, then skyrocketed by 51.49% to $67951.0 in 2025.
  • Its Capital Expenditures was $67951.0 in Q3 2025, compared to $30930.0 in Q2 2025 and $59373.0 in Q1 2025.